Sign up to save your podcasts
Or
Share GeoVax Labs Strengthens Immuno-Oncology Strategy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
GeoVax Labs Strengthens Immuno-Oncology Strategy
GeoVax Labs secures an exclusive license for Gedeptin® + Immune Checkpoint Inhibitor Combination Technology from Emory University, enhancing its IP foundation for solid tumor therapies and clinical programs.
View all episodes
By NewsRampGeoVax Labs secures an exclusive license for Gedeptin® + Immune Checkpoint Inhibitor Combination Technology from Emory University, enhancing its IP foundation for solid tumor therapies and clinical programs.